[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hebrew SeniorLife\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":253},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,80,115,138],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100575380","brain-stimulation-for-foot-sole-sensation-in-older-adults-with-foot-sole-somatosensory-deficits-100575380",false,"NCT06771531","Brain Stimulation for Foot-sole Sensation in Older Adults With Foot-sole Somatosensory Deficits","Cortical Mechanisms and Modulation of Somatosensation in Older Adults With Foot Sole Somatosensory Impairments","BSFS","Inclusion Criteria:\n\n1. Aged ≥65 years.\n2. Self-reported feeling of unsteadiness or difficulty when standing and walking.\n3. Mild-to-moderate foot-sole somatosensory impairment: the ability to perceive 75g monofilament but inability to perceive 10g monofilament.\n\nExclusion Criteria:\n\n1. self-reported inability to stand or walk continuously for one minute without personal assistance (canes or walkers allowed);\n2. history or presence of foot ulceration, amputation, or deformities;\n3. self-reported uncontrolled pain or pain that is associated with mobility disability;\n4. uncontrolled diabetes mellitus;\n5. hospitalization within the past three months due to acute illness, or as the result of a musculoskeletal injury significantly affecting balance;\n6. persistent severe pain of lower extremity when standing or walking;\n7. diagnosis of dementia, Parkinson's disease, or stroke that affects balance;\n8. unstable medical condition;\n9. legal blindness or deafness;\n10. uncontrolled hypertension (i.e., systolic BP \\>180, diastolic BP \\>100 mm Hg, or prescription of ≥3 anti-hypertensive medications);\n11. functionally limiting nephropathy, severe diseases or transplant of the kidney or liver, renal or congestive heart failure;\n12. active cancer treatment;\n13. balance disorders due to past use of chemotherapy or history of Guillain-Barré syndrome;\n14. use of neuro-active or recreational drugs (e.g., sedatives, anti-psychotics), or alcohol abuse, which may affect the brain excitability;\n15. contraindications to MRI or tDCS (e.g., personal or family history of seizures or epilepsy, metallic or electric bio-implants, claustrophobia, brain surgery);\n16. persistent vertigo;\n17. history of Charcot-Marie-Tooth nerve disease.","ALL","65 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","In older adults, diminished sensation of the legs and feet is highly prevalent and causes poor balance and reduced mobility. This type of sensation is not only dependent upon the receptors and nerves in the legs and feet, but also upon a complex central nervous system pathway that includes the cerebral cortex of the brain. This project will use a form of noninvasive brain stimulation called transcranial direct current stimulation (tDCS) to test whether increasing the excitability of the brain networks that process sensory feedback can augment foot sole sensation, balance, and mobility in older adults suffering from mild-to-moderate foot sole sensory impairments.",[27,28,29],"Somatosensory Function","Balance Control","Mobility",[31,32,33],"brain stimulation","balance and mobility","foot-sole somatosensory function","RECRUITING","2026-04-21",{"date":37,"type":38},"2026-04-22","ACTUAL",{"date":40,"type":38},"2026-02-26",{"date":42,"type":21},"2026-12-31",{"name":44,"class":45},"Hebrew SeniorLife","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":46},"100546023","synbiotic-to-attenuate-resorption-of-the-skeleton-100546023","NCT06389539","Synbiotic to Attenuate Resorption of the Skeleton","A Randomized, Double-Blind, Placebo-Controlled, Clinical Food Trial of Probiotic\u002FPrebiotic Medical Food for the Dietary Management of Age Related Bone Loss","STARS","Inclusion Criteria:\n\n* 1\\. Provided written informed consent.\n* 2\\. Stated availability throughout entire study period and willingness to fulfill all details of the protocol.\n* 3\\. Age 60 years and above.\n* 4\\. DXA-BMD of the hip and spine (T-score) \\> -2.5. Women with a BMD T score ≤ -2.5 (i.e. women with low BMD indicating osteoporosis) will also be considered if they have decided not to accept the standard of care use of osteoporosis medications for the entire duration of their participation in the study.\n* 5\\. Women with a history of major low-trauma fragility fractures (hip, forearm, humerus, spine) since the age of 50 years will be considered if they are not currently using osteoporosis medications, or if they have decided not to accept the standard of care osteoporosis medications, even if diagnosed with osteoporosis during the screening procedure.\n* 6\\. Serum 25-hydroxyvitamin D ≥ 20 ng\u002FmL.\n* 7\\. Normal renal function (eGFR \\>50 ml\u002Fmin).\n* 8\\. Have chosen to not accept the standard of care use of osteoporosis medications for the duration of the study.\n* 9\\. Willing to comply with protocol and report on compliance and side effects during the study period.\n\nExclusion Criteria:\n\n* 1\\. BMI greater than 40 kg\u002Fm2.\n* 2\\. Participants consuming dietary supplements (fish oil, probiotics\u002Fprebiotics, and fiber) in the prior month, and unwilling to avoid these supplements for the duration of the study.\n* 3\\. Participants using osmotic laxatives \\>1 per week and unwilling to avoid use for the duration of the study.\n* 4\\. Known or suspected allergies to probiotics, rice, edible fruit extract or berries.\n* 5\\. Antibiotic use in the past 3 months. Participants placed on an antibiotic after enrollment will be retained.\n* 6\\. History of drug and\u002For alcohol abuse at the time of enrolment.\n* 7\\. Presence of any of the following:\n* a. History of other bone disorders (e.g. Paget's disease).\n* b. History of moderate to severe scoliosis.\n* c. History of cancer other than skin cancer \\\u003C5 years in remission, autoimmune disease, immune problems such as AIDS, type 1 or 2 diabetes.\n* d. History of colon resection, any disease that could interfere with the intestinal barrier function such as ulcerative colitis, irritable bowel syndrome or Crohn's disease or any chronic bowel condition.\n* e. Women with untreated hyperparathyroidism.\n* f. History of chronic antibiotic use.\n* g. History of bariatric surgery.\n* h. History of partial colectomy.\n* i. History of pancreatic disease.\n* j. History of active hepatitis B, hepatitis C, cirrhosis, metabolic dysfunction-associated steatotitc liver disease (MASLD), fatty liver or chronic liver disease.\n* k. Current bone marrow disorders such as myelodysplastic syndrome or anemia requiring transfusions.\n* l. Abnormalities of the spine determined by the study physician to interfere with the assessment of bone mineral density.\n* m. Current smoking or use of nicotine products within the past 6 months.\n* n. Current use of marijuana and unwilling to abstain during the study period.\n* o. Major abdominal surgery within the last 3 months.\n* p. Colonoscopy within the last 1 month.\n* q. Colonoscopy planned in the next 18 months and unwilling to reschedule it.\n* r. Indwelling catheter, implanted hardware\u002Fprosthetic device or feeding tube.\n* s. Any medical condition that could interfere with the conduct of the study.\n* 8\\. Treatment with calcitonin, estrogens, selective estrogen receptor modulators, progestins, anabolic steroids, or glucocorticoids in the past 6 months.\n* 9\\. Treatment with bisphosphonates in the past 3 years.\n* 10\\. Previous treatment with parathyroid hormone (PTH), abaloparatide, romosozumab or denosumab in the last year or current coumadin use.\n* 11\\. Current or previous treatment with glucagon-like peptide (GLP-1) receptor agonists in the last one year.\n* 12\\. Participation in other bone, diet, autoimmune, or GI related clinical trials in the last 6 months. If the subject has been in a recent experimental trial, these must have been completed not less than 60 days prior to this study.\n* 13\\. Participants who plan on changing diet and\u002For exercise regime during trial participation.\n* 14\\. Screening laboratory tests greater than upper normal limit (ULN) or less than lower normal limit (LLN):\n* Serum 25-hydroxyvitamin D \\\u003C20 ng\u002FmL\n* Renal dysfunction (eGFR ≤50 ml\u002Fmin)\n* 15\\. Seated blood pressure greater than equal to 160 mm Hg or seated diastolic blood pressure greater than equal to 100mm Hg.\n* 16\\. Short Blessed Test score \\>10 or judged by the research staff as unable to follow the study protocol.\n* 17\\. Any other condition that in the opinion of the investigator or study clinician would jeopardize the safety or rights of the volunteer participating in the study or would make it unlikely the volunteer could complete the study.",true,"FEMALE","60 Years",{"count":59,"type":21},220,[24],"This randomized, double blind, placebo controlled clinical trial will test the efficacy of a probiotic\u002Fprebiotic combination (\"synbiotic\") on the skeleton in older women.",[63,64,65],"Osteoporosis","Inflammation","Aging",[67,68,69,70,71],"Dietary probiotics","Dietary prebiotics","Gut microbiome","Older women","Randomized Controlled Trial","2026-03-13",{"date":74,"type":38},"2026-03-17",{"date":76,"type":38},"2024-08-12",{"date":78,"type":21},"2029-03",{"name":44,"class":45},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":99,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":46},"100490050","non-invasive-brain-stimulation-for-cognitive-and-motor-dysfunction-in-dementia-100490050","NCT05661084","Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia","Multifocal Transcranial Current Stimulation for Cognitive and Motor Dysfunction in Dementia","ACDCStim","Inclusion Criteria:\n\nParticipants (Ps)\n\n* willing and capable to give informed consent for the participation in the study after it has been thoroughly explained\n* able and willing to comply with all study requirements\n* an informed consent form was signed\n* able to read, write, and communicate in English\n\nCaregiver\u002FAdministrators (As)\n\n* at least 18 years of age\n* able to read, write, and communicate in English\n* self-reported computer proficiency and willingness to learn how to use tES as defined by \"yes\" answers to the questions \"Do you feel comfortable using a computer?\" and \"Are you willing to be the primary caregiver for a participant and learn how to administer tES?\"\n* stated availability during weekdays throughout the study period to administer tES to the Ps\n\nExclusion Criteria:\n\nParticipants (Ps)\n\n* major psychiatric co-morbidity including major depressive disorder, schizophrenia or psychosis\n* blindness or other disabilities that prevent task performance\n* contraindications to tES, as recorded on a standardized screening questionnaire, which include a reported seizure within the past two years, use of neuroactive drugs, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant, etc.)\n* the presence of any active dermatological condition, such as eczema, on the scalp a score of 18 or less on the Montreal Cognitive Assessment (MoCA) during the in-person screen\n* an inability to understand study procedures following review of the Informed Consent form\n* Understanding will be assessed by asking the participant to answer the following three questions: 1) What is the purpose of this study? 2) What are the risks of study involvement? 3) If you decide to participate, are you allowed to withdraw from the study at any time? Answers will be recorded by study personnel on the \"Assessment of Protocol Understanding\" form. Insufficient understanding will be defined by one or more incorrect answers, as determined at the discretion of the investigator\n\nCaregiver\u002FAdministrators (As)\n\n* mild cognitive impairment defined by a MoCA score ≤26 during the in-person screen\n* insufficient understanding of study procedures following review of the Informed Consent form\n* Understanding will be assessed by asking the participant to answer the following three questions: 1) What is the purpose of this study? 2) What are the risks of study involvement? 3) If you decide to participate, are you allowed to withdraw from the study at any time? Answers will be recorded by study personnel on the \"Assessment of Protocol Understanding\" form. Insufficient understanding will be defined by one or more incorrect answers, as determined at the discretion of the investigator.\n* poor eyesight, severe arthritis in the hands, pain, deformity or other condition that interferes with successful administration of tES","55 Years",{"count":90,"type":21},144,[24],"This project aims to examine the efficacy of remote, caregiver-led tES\u002Fbrain stimulation intervention targeted to improve memory, mobility, and executive functioning among older adults with mild cognitive impairment or mild dementia.",[94,95,96,97,98],"Dementia","Memory Loss","Alzheimer Disease","Executive Dysfunction","Mobility Limitation",[100,94,101,102,103,104,105,106],"Alzheimer's Disease","Memory","Brain Stimulation","transcranial alternating current stimulation (tACS)","transcranial direct current stimulation (tDCS)","Executive function","instrumental activities of daily living (IADL)","2026-01-08",{"date":109,"type":38},"2026-01-12",{"date":111,"type":38},"2023-01-24",{"date":113,"type":21},"2027-08-31",{"name":44,"class":45},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":46},"100512296","trial-to-reduce-antimicrobial-use-in-nursing-home-residents-with-alzheimers-disease-and-other-dementias-20-100512296","NCT05950607","Trial to Reduce Antimicrobial Use in Nursing Home Residents With Alzheimer's Disease and Other Dementias 2.0","Trial to Reduce Antimicrobial Use In Nursing Home Residents With Alzheimer's Disease and Other Dementias 2.0 (TRAIN-AD 2.0)","TRAIN-AD 2","Inclusion Criteria:\n\n1. Age \\> 60\n2. A diagnosis of dementia (any type)\n3. Cognitive Functional Scale (CFS) \\> 1\n4. NH length of stay \\>90 days\n\nThe CFS score categorizes cognitive impairment status based on data in the electronic health record into: 1. None, 2. Mild, 3. Moderate, and 4. Severe (advanced). For the primary outcome, the analysis will be restricted to residents with a CFS score of 3 or 4.\n\nExclusion Criteria:\n\n1. Less than 60 years of age\n2. Living in nursing home for less than 90 days\n3. Does not have diagnosis of dementia\n4. Does not meet CFS \\>1 score","106 Years",{"count":125,"type":21},750,[24],"The goal of this pragmatic cluster randomized clinical trial is to compare management of suspected infection in nursing home residents with dementia The main questions it aims to answer whether residents with dementia in nursing homes randomized to use a multicomponent intervention to optimize suspected infection management ( versus usual care) use less antibiotics and fewer burdensome interventions.",[94,96,129],"Infections","2026-01-02",{"date":132,"type":38},"2026-01-06",{"date":134,"type":38},"2023-11-13",{"date":136,"type":21},"2026-06-30",{"name":44,"class":45},{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":22,"phases":149,"briefSummary":150,"conditions":151,"keywords":155,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":252},"100579228","home-based-brain-stimulation-for-motoric-cognitive-risk-syndrome-100579228","NCT06821568","Home-Based Brain Stimulation for Motoric Cognitive Risk Syndrome","Long-term Home-based Transcranial Electrical Stimulation for Cognitive and Motor Function in Older Adults With an Increased Risk of Dementia: a Randomized Controlled Trial","TDCS4MCR","Inclusion Criteria:\n\n* Men and women\n* Age 65-90 years\n* Subjective cognitive complaints as defined by a 'Yes' response to \"Do you feel that you have more problems with memory than most?\" or a 'No' response to \"is your mind as clear as it used to be?\"\n* Montreal Cognitive Assessment (MoCA) score ≥21\n* Slow gait speed as measured by averaging two 4-Meter walks and defined as a usual walking speed one standard deviation below age and sex-adjusted means.\n* Absence of significant disability as defined by the ability to walk over the instrumented gait mat unassisted (e.g., able to walk without any walking aids for at least 2 minutes non-stop) and preserved activities of daily living as defined by a score of less than 9 on the Functional Activities Questionnaire.\n* Identification of an eligible informant\n* Identification of a willing and able tDCS-administrator; i.e., a study partner to lead the administration of home-based transcranial direct current stimulation (tDCS)\n* Access to reliable WiFi in the participant's home\n\nExclusion Criteria:\n\n* Formal education less than the 8th grade\n* Previous physician diagnosis of dementia\n* Any current diagnosis of a major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depressive disorder)\n* Evidence of moderate-to-severe depressive symptoms defined by a score of ≥9 on the 15-item Geriatric Depression Scale\n* History of head trauma resulting in prolonged loss of consciousness\n* History of fainting spells of unknown or undetermined etiology that might constitute seizures\n* History of seizures, diagnosis of epilepsy, or immediate (first-degree relative) family history of epilepsy except for a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist\n* Hospitalization within the past three months due to acute illness, or as the result of a musculoskeletal injury significantly affecting gait or balance\n* Any unstable medical condition or chronic (particularly) uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.) or study complication\n* Substance use disorders within the past six months\n* A hairstyle or headdress that prevents electrode contact with the scalp or would interfere with the stimulation (for example thick braids, hair weave, afro, wig)\n* Chronic vertigo\n* Myocardial infarction within the past 6 months\n* Active cancer for which chemo-\u002Fradiation therapy is being received\n* Legal blindness\n* Visual hallucinations (history or self-report)\n* Pacemaker\n* Contraindications to MRI or tDCS, including unprovoked seizure within the past two years, risk of ferromagnetic objects anywhere in the body, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant, pacemaker, etc.), the presence of any active dermatological condition, such as eczema, on the scalp, etc. as outlined by current recommendations for noninvasive brain stimulation endorsed by the International Federation for Clinical Neurophysiology.\n* History of REM sleep behavior disorder (RBD), often an early sign of Parkinson's disease\n* Medications and medical history will be reviewed by the responsible covering physician and a decision about inclusion will be made based on the participant's past medical history, drug dose, history of recent medication changes or duration of treatment, and combination with other CNS active drugs.","90 Years",{"count":148,"type":21},128,[24],"The objective of this study is to determine the effects of a 6-month, home-based personalized transcranial direct current stimulation (tDCS) intervention targeting the left dorsolateral prefrontal cortex on cognitive function, dual task standing and walking, and other metrics of mobility in older adults with motoric cognitive risk syndrome (MCR).",[152,153,154],"Alzheimer Disease and Related Dementias","Cognition","Mobility Disability",[156,157,158,159,160,161,162,163,164,94,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243],"Anatomy","Anxiety","Atrophic","Behavioral","Brain","Brain Region","Cephalic","Cognitive","Communities","Development","Dose","Double-Blind Method","Electric Stimulation","Enrollment","Evaluation","Exhibits","Exposure to","Frequencies","Future","Gait","Gait Speed","Genetic Crossing Over","Home","Impaired Cognition","Individual","Intervention","Intervention Studies","Magnetic Resonance Imaging","Measurable","Measures","Mood","Motor","Multi-Institutional Clinical Trial","Neuronal Plasticity","Outcome","Participant","Performance","Phase","Pilot Projects","Prefrontal Cortex","Randomized","Randomized Controlled Clinical Trials","Research","Resolution","Rest","Risk","Series","Site","Structure","Testing","Therapeutic","Time","Syndrome","Walking","Work","Arm","cerebral atrophy","Clinically relevant","cognitive task","Cost","Dementia Risk","Design","Executive Function","functional improvement","functional near infrared spectroscopy","Gray Matter","high risk","home test","improved","insight","late life","mental function","neural network","neuroimaging","noninvasive brain stimulation","normal aging","older adult","older men","older women","open label","primary endpoint","response","secondary outcome","smartphone application","transcranial direct current stimulation","trial design","walking speed","Alzheimer's Disease","2025-09-17",{"date":246,"type":38},"2025-09-22",{"date":248,"type":38},"2025-09-02",{"date":250,"type":21},"2029-06",{"name":44,"class":45},2,""]